↓ Skip to main content

Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo

Overview of attention for article published in Molecular Neurodegeneration, December 2009
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (83rd percentile)
  • Good Attention Score compared to outputs of the same age and source (75th percentile)

Mentioned by

blogs
1 blog
f1000
1 research highlight platform

Citations

dimensions_citation
39 Dimensions

Readers on

mendeley
54 Mendeley
connotea
1 Connotea
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Acute dosing of latrepirdine (Dimebon™), a possible Alzheimer therapeutic, elevates extracellular amyloid-β levels in vitro and in vivo
Published in
Molecular Neurodegeneration, December 2009
DOI 10.1186/1750-1326-4-51
Pubmed ID
Authors

John W Steele, Soong H Kim, John R Cirrito, Deborah K Verges, Jessica L Restivo, David Westaway, Paul Fraser, Peter St George Hyslop, Mary Sano, Ilya Bezprozvanny, Michelle E Ehrlich, David M Holtzman, Sam Gandy

Abstract

Recent reports suggest that latrepirdine (Dimebon, dimebolin), a retired Russian antihistamine, improves cognitive function in aged rodents and in patients with mild to moderate Alzheimer's disease (AD). However, the mechanism(s) underlying this benefit remain elusive. AD is characterized by extracellular accumulation of the amyloid-beta (Abeta) peptide in the brain, and Abeta-lowering drugs are currently among the most popular anti-amyloid agents under development for the treatment of AD. In the current study, we assessed the effect of acute dosing of latrepirdine on levels of extracellular Abeta using in vitro and in vivo experimental systems.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 2%
Belgium 1 2%
Canada 1 2%
Unknown 51 94%

Demographic breakdown

Readers by professional status Count As %
Researcher 14 26%
Student > Master 9 17%
Student > Ph. D. Student 6 11%
Student > Bachelor 6 11%
Professor 4 7%
Other 9 17%
Unknown 6 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 15 28%
Neuroscience 10 19%
Biochemistry, Genetics and Molecular Biology 7 13%
Chemistry 4 7%
Medicine and Dentistry 4 7%
Other 7 13%
Unknown 7 13%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 February 2010.
All research outputs
#4,648,822
of 22,661,413 outputs
Outputs from Molecular Neurodegeneration
#524
of 842 outputs
Outputs of similar age
#24,280
of 151,044 outputs
Outputs of similar age from Molecular Neurodegeneration
#2
of 8 outputs
Altmetric has tracked 22,661,413 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 842 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.0. This one is in the 37th percentile – i.e., 37% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 151,044 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 83% of its contemporaries.
We're also able to compare this research output to 8 others from the same source and published within six weeks on either side of this one. This one has scored higher than 6 of them.